Sheila Hollins, Suzy Lishman, Georgina Starling, Ruslan Zinchenko
{"title":"Untested, unlicensed, unregulated: prescribing and oversight issues in physician-assisted dying/suicide.","authors":"Sheila Hollins, Suzy Lishman, Georgina Starling, Ruslan Zinchenko","doi":"10.1136/spcare-2025-005612","DOIUrl":null,"url":null,"abstract":"<p><p>Current lethal combinations and doses of drugs used in physician-assisted dying/suicide are untested, unlicensed and unregulated, with little pharmacological understanding of efficacy and safety at high doses. Despite this, the proposed legislation would bypass regulatory safeguards, licensing, adverse event reporting and coroner referral. In any other area of medicine, such practices would be unacceptable. Before legalisation, we recommend that a formal, prospective clinical trial should be undertaken to establish the safety, efficacy and acceptability of different practices in end-of-life care including any use of lethal drug combinations. We also suggest that prescribing, licensing and monitoring gaps should be addressed.</p>","PeriodicalId":9136,"journal":{"name":"BMJ Supportive & Palliative Care","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Supportive & Palliative Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/spcare-2025-005612","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Current lethal combinations and doses of drugs used in physician-assisted dying/suicide are untested, unlicensed and unregulated, with little pharmacological understanding of efficacy and safety at high doses. Despite this, the proposed legislation would bypass regulatory safeguards, licensing, adverse event reporting and coroner referral. In any other area of medicine, such practices would be unacceptable. Before legalisation, we recommend that a formal, prospective clinical trial should be undertaken to establish the safety, efficacy and acceptability of different practices in end-of-life care including any use of lethal drug combinations. We also suggest that prescribing, licensing and monitoring gaps should be addressed.
期刊介绍:
Published quarterly in print and continuously online, BMJ Supportive & Palliative Care aims to connect many disciplines and specialties throughout the world by providing high quality, clinically relevant research, reviews, comment, information and news of international importance.
We hold an inclusive view of supportive and palliative care research and we are able to call on expertise to critique the whole range of methodologies within the subject, including those working in transitional research, clinical trials, epidemiology, behavioural sciences, ethics and health service research. Articles with relevance to clinical practice and clinical service development will be considered for publication.
In an international context, many different categories of clinician and healthcare workers do clinical work associated with palliative medicine, specialist or generalist palliative care, supportive care, psychosocial-oncology and end of life care. We wish to engage many specialties, not only those traditionally associated with supportive and palliative care. We hope to extend the readership to doctors, nurses, other healthcare workers and researchers in medical and surgical specialties, including but not limited to cardiology, gastroenterology, geriatrics, neurology, oncology, paediatrics, primary care, psychiatry, psychology, renal medicine, respiratory medicine.